Evidence map›Paper›PMID 41316838›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2026

Association of Epigenetic Aging Biomarkers With Risk of MASLD-Related HCC.

Alani Perkin, Sebastian M Armasu, Winnie Z Fan, Naana N Yalley, Irene K Yan, Fowsiyo Y Ahmed, Laura Izquierdo-Sanchez, Loreto Boix, Angela Rojas, Jesus M Banales and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Alani PerkinMayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Sebastian M ArmasuDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Winnie Z FanDivision of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.
Naana N YalleyDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
Irene K YanDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Fowsiyo Y AhmedDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0002-0201-6706
Laura Izquierdo-SanchezDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute-Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, San Sebastian, Spain.
Loreto BoixBCLC Group, Liver Unit, ICMDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.
Angela RojasSeLiver Group, UCM Digestive Diseases, Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain.
Jesus M BanalesDepartment of Liver and Gastrointestinal Diseases, Biogipuzkoa Health Research Institute-Donostia University Hospital, University of the Basque Country (UPV/EHU), CIBERehd, San Sebastian, Spain.ORCID 0000-0002-5224-2373
Maria ReigBCLC Group, Liver Unit, ICMDM, IDIBAPS, Hospital Clinic of Barcelona, University of Barcelona, Barcelona, Spain.
Per StålDepartment of Upper GI Diseases, Karolinska University Hospital, Stockholm, Sweden.
Manuel Romero GómezSeLiver Group, UCM Digestive Diseases, Institute of Biomedicine of Seville (IBiS), Virgen del Rocio University Hospital/CSIC/University of Seville, Seville, Spain.ORCID 0000-0001-8494-8947
Amit G SingalDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.ORCID 0000-0002-1172-3971
Lewis R RobertsDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Kirk J WangensteenDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Anders BerglundDivision of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.
Tushar PatelDepartment of Cancer Biology, Mayo Clinic, Jacksonville, Florida, USA.
Samuel O AntwiDivision of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Jacksonville, Florida, USA.

Funding

Project 4: ImmunovirotherapyP50CA210964 · NCI · MAYO CLINIC ROCHESTER · PI MARK A. MC NIVEN · 2018 to 2026
$20.5M
Clinical Validation Center for Hepatocellular CarcinomaU01CA271887 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI FASIHA KANWAL, JORGE A MARRERO · 2022 to 2026
$4.7M
Precision Risk Stratification and Screening for HCC among Patients with Indeterminate Liver NodulesU01CA283935 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HOSHIDA, YUJIN, SINGAL, AMIT · 2023 to 2025
$3.9M
Hereditary Genetics of Hepatocellular CarcinomaR37CA259201 · NCI · MAYO CLINIC ROCHESTER · PI Kirk J Wangensteen · 2022 to 2026
$3.3M
Integrated molecular epidemiologic analysis of the one-carbon metabolism pathway and risk of HCCK01CA237875 · NCI · MAYO CLINIC JACKSONVILLE · PI ANTWI, SAMUEL O. · 2020 to 2024
$829k
NCI NIH HHS K01 CA237875NCI NIH HHS L30 CA209733NIH HHS P50 295495NIH HHS P50 CA210964NIH HHS P50 CA210964-02A1CEPNIH HHS R37 CA259201NIH HHS U01 CA271887NIH HHS U01 CA283935
6 · The paper itself

Abstract

introductionHepatocellular carcinoma (HCC) development in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is a growing health concern, but the underlying mechanisms are not fully understood. Epigenetic aging biomarkers, reflecting cellular and tissue aging, have been linked to various age-related pathologies, but their association with MASLD-HCC is unknown. We investigated associations between five epigenetic aging biomarkers and MASLD-HCC risk.

methodsWe performed whole blood DNA methylation assay (Infinium 850k array) and calculated principal components-based (PC) versions of HorvathAge, HannumAge, PhenoAge and GrimAge and the DunedinPACE aging rate. We further calculated relative age accelerations for PCHorvathAge, PCHannumAge, PCPhenoAge and PCGrimAge. The aging biomarkers were modelled as continuous variables and categorised into tertiles based on distributions among controls. Associations between each aging biomarker and MASLD-HCC were examined using logistic regression, calculating odds ratios (ORs) and 95% confidence intervals (CIs), adjusting for covariates.

resultsData on 272 MASLD-HCC cases and 316 cancer-free MASLD controls recruited from six sites and matched on chronological age, sex and study site were analysed. Higher relative age accelerations of PCPhenoAge (OR

conclusionHigher relative age accelerations of PCPhenoAge, PCGrimAge and DunedinPACE aging rate are associated with risk of MASLD-HCC. These aging biomarkers could improve HCC risk assessment and facilitate risk stratification in patients with MASLD.

Indexed as

AgingCarcinoma, HepatocellularEpigenesis, GeneticFatty LiverLiver NeoplasmsAdultAgedBiomarkersCase-Control StudiesDNA MethylationFemaleHumansLogistic ModelsMaleMiddle AgedRisk FactorsBiomarkersaging biomarkersaging clocksepigeneticHCCliver cancer

Identifiers

PMID41316838
PMCPMC13135749

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.